Biodesix to Provide COVID-19 Testing for Colorado State University Campus

Biodesix, Inc., a leading diagnostic company with a focus in lung disease, today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to...

Learn More

Terumo BCT Revamps Brand

Terumo BCT is revamping its brand to Terumo Blood and Cell Technologies to reflect the company promise to unlock the potential of blood and cells and its heritage to innovate with customers to serve m...

Learn More

Sana Health raises $5.8M to get through clinical trials

Sana Health Inc., is currently in the middle of its trials for the behavioral health device that uses a relaxation mask to relieve chronic pain and stress. Sana has raised $5.8 million in new venture...

Learn More

TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales

SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. TriSalus plans to further develop SD-101 as an oncology therapeutic. F...

Learn More

Colorado-based New Iridium accelerating global production of potential COVID-19 treatment using light-driven chemistry

New Iridium, a company developing commercialized  photocatalysis technologies to accelerate drug development and manufacturing, has been awarded a National Science Foundation (NSF) Small Business Tech...

Learn More

KromaTiD Announces Launch of New Product, dGH In-Site™

KromaTiD, Inc. announced today the launch of its new product dGH In-Site™, a single-cell, high resolution, genome-wide DNA insert tracking assay. dGH In-Site™ enables researchers to directly measure t...

Learn More

Boulder Biotech Company to be Acquired for $1.4B

Just a few weeks ago, the company filed for an IPO. Now, it's being acquired. Find out more in the article from Denver Business Journal.

Learn More

Brickell Biotech, Inc. Announces Pricing of $20.1 Million Underwritten Public Offering

Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitati...

Learn More

Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer

Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Kirsten L. Gruis, M.D., M.S. to the newly create...

Learn More

ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring (PCM™) to Clinical Research

ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM™) assays to understand the potential benefits of minim...

Learn More